Oppositional defiant disorder (ODD)
Also known as: Disorder, Syndrome, Diseases, Condition
Methodology & AI Transparency ⓘ
Oppositional defiant disorder (ODD) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinical triage of Oppositional defiant disorder (ODD) (also termed Disorder or Syndrome) (F91.3) in Depression & Mood relies on medication response pharmacogenomics [Oppositional defiant disorder (ODD) F91.3], guiding step-wise therapeutic adjustments toward Serum Vitamin D in Oppositional defiant disorder (ODD) (F91.3: & RBC Folate) (25(OH)D 40 – 65 ng/mL (F91.3)).
- 2 Real-world patient consensus: Clinical coding for Oppositional defiant disorder (ODD) uses ICD-10 F91.3 across Depression & Mood specialty care.
- 3 Typical cash cost range: Workup highlights for Oppositional defiant disorder (ODD) (F91.3): medication response pharmacogenomics [Oppositional defiant disorder (ODD) F91.3].
- 4 Top reported side effects / signs: Follow-up benchmark in Oppositional defiant disorder (ODD): maintaining TSH & Free in Oppositional defiant disorder (ODD) (F91.3: T4 Rule-Out) within TSH 0.8 – 2.5 mIU/L (F91.3).
Ask our AI Specialists anything about Oppositional defiant disorder (ODD)
What Is Oppositional defiant disorder (ODD)?
Clinical triage of Oppositional defiant disorder (ODD) (also termed Disorder or Syndrome) (F91.3) in Depression & Mood relies on medication response pharmacogenomics [Oppositional defiant disorder (ODD) F91.3], guiding step-wise therapeutic adjustments toward Serum Vitamin D in Oppositional defiant disorder (ODD) (F91.3: & RBC Folate) (25(OH)D 40 – 65 ng/mL (F91.3)).
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Oppositional defiant disorder (ODD) (code F91.3) is hypothalamic-pituitary-adrenal (HPA) axis in Oppositional defiant disorder (ODD) (F91.3: cortisol hyperactivity), which Depression, Bipolar & Mood Disorders clinicians address while surveilling TSH & Free in Oppositional defiant disorder (ODD) (F91.3: T4 Rule-Out) (TSH 0.8 – 2.5 mIU/L (F91.3)).
Common Symptoms & Clinical Signs
- • Presentation of Oppositional defiant disorder (ODD) (F91.3): slowed concentration, indecisiveness, in Oppositional defiant disorder (ODD) (F91.3: and physical heaviness)
- • Secondary Oppositional defiant disorder (ODD) clinical sign: loss of interest in Oppositional defiant disorder (ODD) (F91.3: or pleasure in)
- • Symptom flares in Oppositional defiant disorder (ODD) correlating with TSH & Free in Oppositional defiant disorder (ODD) (F91.3: T4 Rule-Out) deviation outside TSH 0.8 – 2.5 mIU/L (F91.3)
- • Functional depression & mood impact requiring medication response pharmacogenomics [Oppositional defiant disorder (ODD) F91.3] evaluation (F91.3)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Oppositional defiant disorder (ODD) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F91.3 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Depression, Bipolar & Mood Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: TSH & Free in Oppositional defiant disorder (ODD) (F91.3: T4 Rule-Out) | TSH 0.8 – 2.5 mIU/L (F91.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Vitamin D in Oppositional defiant disorder (ODD) (F91.3: & RBC Folate) | 25(OH)D 40 – 65 ng/mL (F91.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: PHQ-9 Symptom Severity in Oppositional defiant disorder (ODD) (F91.3: Score) | < 4 (clinical remission) (F91.3) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Oppositional defiant disorder (ODD)
Treatment selection for Oppositional defiant disorder (ODD) depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Oppositional defiant disorder (ODD))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Efficacy, tolerability, and acceptability of bupropion for: What a 1,117-Participant Study Found According to the limited data obtained from three RCTs, bupropion XL is as effective and tolerable as venlafaxine XR for adult patients with MDD. Drug design, development and therapy • 2013-01-15 • Meta-Analysis | N = 1,117 | 94/100 | PMID 24101861 ↗ |
| New Insights on Benefits and safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With: What a 327-Participant Study Found Conclusions: In this phase 3 trial in patients with MDD, treatment with dextromethorphan-bupropion (AXS-05) resulted in significant improvements in depressive symptoms compared to placebo starting 1 week after treatment... The Journal of clinical psychiatry • 2022-05-30 • Phase III Randomized Trial | N = 327 | 93/100 | PMID 35649167 ↗ |
| Can This Approach Help? Inside the Latest Research on Antipsychotic Medication on Brain Structure in Patients With depression and Eighty-eight participants (age range, 18-85 years) completed a baseline scan; 75 completed a follow-up scan, of which 72 (32 men and 40 women) were useable for final analyses. JAMA psychiatry • 2020-07-01 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 32101271 ↗ |
| Can This Approach Help? Inside the Latest Research on Sexual Function With Adjunctive Lumateperone in Patients With Conclusions: Adjunctive lumateperone 42 mg did not worsen sexual functioning and was not associated with treatment-related sexual dysfunction in patients with MDD with inadequate response to ADT. The Journal of clinical psychiatry • 2026-09-02 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 42690086 ↗ |
| Can This Approach Help? Inside the Latest Research on Shared and Unique Changes in Brain Connectivity Among Depressed Patients After Full symptom relief from major depression via treatment with CBT or medication is associated with changes in rsFC that are mostly specific to the treatment modality, providing biological support for the clinical practice of... The American journal of psychiatry • 2023-03-01 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 36651624 ↗ |
Oppositional defiant disorder (ODD) Patient Community & “People Like Me” Threads
Filter Oppositional defiant disorder (ODD) community threads and patient logs by age, biological sex, dosage, and treatment duration.